3-hydroxy-4-methoxybenzylsulfonylacetic acid | 865783-98-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3-hydroxy-4-methoxybenzylsulfonylacetic acid
• 英文别名: 3-hydroxy-4-methoxy benzyl sulfoneacetic acid；2-((3-hydroxy-4-methoxybenzyl)sulfonyl)acetic acid；2-[(3-hydroxy-4-methoxyphenyl)methylsulfonyl]acetic acid
• CAS: 865783-98-8
• 化学式: C₁₀H₁₂O₆S
• 分子量: 260.268
• InChiKey: NZBDUJVZYKLXOO-UHFFFAOYSA-N

物化性质

• 熔点：
  164-165 °C
• 沸点：
  583.9±50.0 °C(Predicted)
• 密度：
  1.471±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-hydroxy-4-methoxybenzylsulfonylacetic acid 在 哌啶 、 四溴化碳 、 三乙胺 、 苯甲酸 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 5.17h， 生成 (E)-2,4,6-trimethoxystyryl-3-O-bis(benzyl)phosphoryl-4-methoxybenzylsulfone
  参考文献：
  名称：

  Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders

  摘要：

  公式（I）的取代酚衍生物可用作抗增殖剂，包括例如抗癌剂，以及放射防护和化学防护剂。

  公开号：

  US20080058290A1
• 作为产物：
  描述：

  3-[(tert-butyldimethylsilyl)oxy]-4-methoxybenzylthioacetic acid 以60的产率得到3-hydroxy-4-methoxybenzylsulfonylacetic acid
  参考文献：
  名称：

  Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders

  摘要：

  公式（I）的取代苯酚衍生物可用作抗增殖剂，包括例如抗癌剂，以及放射保护和化学保护剂。

  公开号：

  US20080058290A1

文献信息

• PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS
  申请人：SIRIGIREDDY REDDY

  公开号：US20100152491A1

  公开（公告）日：2010-06-17

  Processes for preparing (E)-2,4,6-(Trimethoxystyryl)-3-O-Phosphate Disodium-4-Methoxybenzyl Sulfones and uses thereof as antiproliferative agents, including, for example, anticancer agents, and as radioprotective and chemoprotective agents.

  制备(E)-2,4,6-(三甲氧基苯乙烯基)-3-O-磷酸二钠-4-甲氧基苯甲基磺酮的方法及其作为抗增殖剂的用途，包括作为抗癌剂，以及作为放射保护和化学保护剂的用途。
• Composition and Methods For the Treatment of Proliferative Diseases
  申请人：Reddy E. Premkumar

  公开号：US20080161252A1

  公开（公告）日：2008-07-03

  Methods and compositions are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula I: wherein R 1 is selected from the group consisting of —OH, —NH 2 , —NH—CH 2 —CO 2 H, —NH—CH(CH 3 )—CO 2 H, and —NH—C(CH 3 ) 2 —CO 2 H, or a pharmaceutically acceptable salt of such a compound; and an anthracycline, e.g. doxorubicin, or a pharmaceutically acceptable salt thereof, or a platin, e.g. oxaliplatin, or a pharmaceutically acceptable salt thereof.

  提供了用于治疗增生性疾病的方法和组合物，其中该组合物包含至少一种符合式I的化合物，其中R1选自以下群体：—OH，—NH2，—NH—CH2—CO2H，—NH—CH（CH3）—CO2H和—NH—C（CH3）2—CO2H，或该化合物的药学上可接受的盐；以及蒽环类化合物，例如多柔比星或其药学上可接受的盐，或铂类化合物，例如奥沙利铂或其药学上可接受的盐。
• Composition and methods for the treatment of proliferative diseases
  申请人：Temple University - Of The Commonwealth System of Higher Education

  公开号：US08106033B2

  公开（公告）日：2012-01-31

  Methods and compositions are provided for treating proliferative disorders, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —OH, —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and an anthracycline, e.g. doxorubicin, or a pharmaceutically acceptable salt thereof, or a platin, e.g. oxaliplatin, or a pharmaceutically acceptable salt thereof.

  提供了一种治疗增殖性疾病的方法和组合物，其中该组合物包括至少一种按照式I的化合物：其中R1选自以下组中的一种：—OH，—NH2，—NH—CH2—CO2H，—NH—CH(CH3)—CO2H和—NH—C(CH3)2—CO2H，或该化合物的药学上可接受的盐；以及蒽环类化合物，例如阿霉素或其药学上可接受的盐，或铂类化合物，例如奥沙利铂或其药学上可接受的盐。
• WO2008/33475
  申请人：——

  公开号：——

  公开（公告）日：——
• Design, Synthesis, and Biological Evaluation of (<i>E</i>)-Styrylbenzylsulfones as Novel Anticancer Agents
  作者：M. V. Ramana Reddy、Muralidhar R. Mallireddigari、Stephen C. Cosenza、Venkat R. Pallela、Nabisa M. Iqbal、Kimberly A. Robell、Anthony D. Kang、E. Premkumar Reddy

  DOI：10.1021/jm701077b

  日期：2008.1.1

  Cell cycle progression is regulated by cyclins and cyclin-dependent kinases, which are formed at specific stages of the cell cycle and regulate the G1/S and G2/M phase transitions, employing a series of "checkpoints" governed by phosphorylation of their substrates. Tumor development is associated with the loss of these checkpoint controls, and this provides an approach for the development of therapeutic agents that can specifically target tumor cells. Here, we describe the synthesis and SAR of a novel group of cytotoxic molecules that selectively induce growth arrest of normal cells in the G1 phase while inducing a mitotic arrest of tumor cells resulting in selective killing of tumor cell populations with little or no effect on normal cell viability. The broad spectrum of antitumor activity in vitro and xenograft models, lack of in vivo toxicity, and drug resistance suggest potential for use of these agents in cancer therapy.